PH-Sensitive NMDA inhibitors improve outcome in a murine model of SAH

Neurocritical Care

Volumn 20, Issue 1, 2014, Pages 119-131

  Wang, Haichen ^a,b   James, Michael L ^a,b   Venkatraman, Talaignair N ^a,b   Wilson, Lawrence J ^c   Lyuboslavsky, Polina ^c   Myers, Scott J ^c   Lascola, Christopher D ^a,b   Laskowitz, Daniel T ^a,b  

^a Multidisciplinary Neuroprotection Laboratories   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NeurOp Inc   (United States)

Author keywords

Excitotoxicity; Neuroprotection; pH; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

1 (4 (3 (4 (4 CHLOROPHENYL)PIPERAZIN 1 YL) 2 HYDROXYPROPOXY)PHENYL)UREA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; NP 10075; NP 10191; UNCLASSIFIED DRUG; CALCIUM CHANNEL BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NR2B NMDA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG POTENCY; DRUG TOLERABILITY; HEMODYNAMICS; HYPERGLYCEMIA; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE CEREBRAL ARTERY; MOUSE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PH; PLASMA HALF LIFE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUBARACHNOID HEMORRHAGE; VASOSPASM; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; RANDOMIZATION;

ANIMALS; BEHAVIOR, ANIMAL; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; HYDROGEN-ION CONCENTRATION; HYPERGLYCEMIA; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NIMODIPINE; RANDOM ALLOCATION; RECEPTORS, N-METHYL-D-ASPARTATE; SUBARACHNOID HEMORRHAGE;

EID: 84894562862     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9944-9     Document Type: Article

References (42)

1. Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke. 1996;27(4):625-9.
2. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306-18.
3. Locksley HB. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Based on 6,368 cases in the cooperative study. J Neurosurg. 1966;25(2):219-39.
4. Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G. Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington. Neurology. 1993;43(4):712-8.
5. Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003;98(5):978-84.
6. Gump W, Laskowitz DT. Management of post-subarachnoid hemorrhage vasospasm. Curr Atheroscler Rep. 2008;10(4):354-60.
7. Dearden NM. Mechanisms and prevention of secondary brain damage during intensive care. Clin Neuropathol. 1998;17(4):221-8.
8. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci. 2002;5(Suppl):1039-42.
9. Choi D. Antagonizing excitotoxicity: a therapeutic strategy for stroke? Mt Sinai J Med. 1998;65(2):133-8.
10. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets. 2001;2(3):241-71.
11. Low SJ, Roland CL. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther. 2004;42(1):1-14.
12. Kornhuber J, Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry. 1997;41(2):135-44.
13. Lutsep HL, Clark WM. Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R D. 1999;1(1):3-8.
14. Giffard RG, Monyer H, Christine CW, Choi DW. Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res. 1990;506(2):339-42.
15. +. Proc Natl Acad Sci USA. 1990;87(16):6445-9.
16. Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-d-aspartate receptors in cerebellar neurons. Nature. 1990;345(6273):347-50.
17. + sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J Physiol. 1991;433:727-63.
18. Vyklicky L Jr, Vlachova V, Krusek J. The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J Physiol. 1990;430:497-517.
19. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci. 1998;1(8):659-67.
20. +] in the hippocampus during recovery from short-term, transient ischemia. J Cereb Blood Flow Metab. 1992;12(5):759-72.
21. Katsura K, Asplund B, Ekholm A, Siesjo BK. Extra- and intra-cellular pH in the brain during ischaemia, related to tissue lactate content in normo- and hyper-capnic rats. Eur J Neurosci. 1992;4(2):166-76.
22. McEvoy RC, Andersson J, Sandler S, Hellerstrom C. Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest. 1984;74(3):715-22.
23. Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res. 2002;24(5):510-6.
24. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9(8):1085-90.
25. Mesis RG, Wang H, Lombard FW, Yates R, Vitek MP, Borel CO, et al. Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg Focus. 2006;21(3):E4.
26. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874(2):123-30.
27. Wang H, Durham L, Dawson H, Song P, Warner DS, Sullivan PM, et al. An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience. 2007;144(4):1324-33.
28. Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci. 1998;18(16):6163-75.
29. Takata K, Sheng H, Borel CO, Laskowitz DT, Warner DS, Lombard FW. Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2009;21(4):326-33.
30. Sun PZ, Zhou J, Sun W, Huang J, van Zijl PC. Detection of the ischemic penumbra using pH-weighted MRI. J Cereb Blood Flow Metab. 2007;27(6):1129-36.
31. Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505-17.
32. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636-42.
33. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology. 1999;38(5):611-23.
34. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci. 1996;17(6):227-33.
35. Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18(4):485-92.
36. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents toward an understanding of their favorable tolerability. Amino Acids. 2000;19(1):133-49.
37. Bian L, Liu L, Wang C, Hussain M, Yuan Y, Liu G, Wang W, Zhao X. Hyperglycemia within day 14 of aneurysmal subarachnoid hemorrhage predicts 1-year mortality. Clin Neurol Neurosurg. 2013;115(7):959-64.
38. Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol. 2002;52(1):20-8.
39. Schlenk F, Vajkoczy P, Sarrafzadeh A. Inpatient hyperglycemia following aneurysmal subarachnoid hemorrhage: relation to cerebral metabolism and outcome. Neurocrit Care. 2009;11(1):56-63.
40. Holmgaard K, Aalkjaer C, Lambert JD, Bek T. N-Methyl-d-aspartic acid causes relaxation of porcine retinal arterioles through an adenosine receptor-dependent mechanism. Invest Ophthalmol Vis Sci. 2008;49(10):4590-4.
41. Busija DW, Bari F, Domoki F, Louis T. Mechanisms involved in the cerebrovascular dilator effects of N-methyl-d-aspartate in cerebral cortex. Brain Res Rev. 2007;56(1):89-100.
42. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752-8.